Sarepta Therapeutics, Inc.
SRPT· Nasdaq
SRPTSarepta Therapeutics, Inc.
Filed Feb 28, 2024 · 10-K · 59 days after period end · 0000950170-24-022036
derived · Computed from the longer spans the company filed.
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020 |
|---|---|---|---|---|
| Revenue | $463.53M | $235.93M | $178.73M | $122.64M |
| Net Income | $45.66M | -$109.24M | -$121.98M | -$189.32M |
| EPS Diluted | — | — |
Sarepta Therapeutics, Inc. · CIK 873303 · Engraved from SEC EDGAR
| — |
| -$2.40 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2023 · filed Feb 28, 2024 · 59 d after period end
